 | Up a level |
Faehling, M., Schumann, C., Christopoulos, P., Hoffknecht, P., Alt, J., Horn, M., Eisenmann, S., Schlenska-Lange, A., Aries, S. P., Sackmann, S., Schuett, P., Steger, F. and Christoph, D. (2020). Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). Ann. Oncol., 31. S. S806 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Frost, N., Christopoulos, P., Kauffmann-Guerrero, D., Stratmann, J. A., Riedel, R., Schaefer, M., Alt, J., Guetz, S., Brinkmann, J. and Griesinger, F. (2020). Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program. Ann. Oncol., 31. S. S874 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Sebastian, M., Reck, M., Fischer, R. N., Christoph, D. C. C., Bernhardt, C., von der Heyde, E., Nusch, A., Ludwig, P., Hipper, A., Hanselmann, J., Medinger, T., Binninger, A., Jaenicke, M., Christopoulos, P., Elender, C., Bethge, A., Seese, B., Gauler, T. C. and Waller, C. (2022). First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). Ann. Oncol., 33 (7). S. S1252 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041